ACA
WHWK

Acorn Capital Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Acorn Capital Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93M Hold
1,139,363
– – 1.12% 15
2025
Q4 		$2.76M Hold
1,139,363
– – 0.93% 16
2025
Q3 		$2.16M Hold
1,139,363
– – 1.1% 16
2025
Q2 		$2.13M Hold
1,139,363
– – 1.39% 15
2025
Q1 		$2.03M Sell
1,139,363
-7,689
-0.7% -$20.1K 1.35% 15
2024
Q4 		$3.62M Buy
+1,147,052
New +$2.6M 1.95% 15

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Acorn Capital Advisors's WHWK Position: Q1 2026 in Review

Acorn Capital Advisors held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 1,139,363 shares worth $3.93M. The position accounts for 1.12% of the portfolio, ranked #15.

Acorn Capital Advisors first reported a position in WHWK in Q4 2024 and has held it in 6 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Acorn Capital Advisors held 1,139,363 shares of Whitehawk Therapeutics worth $3.93M as of Q1 2026.
  • Acorn Capital Advisors left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 1.12% of Acorn Capital Advisors's portfolio in Q1 2026, its #15 holding.
  • Acorn Capital Advisors first reported a position in Whitehawk Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.